People

Joshua D Lee
Joshua D. Lee, MD, MSc
NYU Langone Health - Associate Professor, Department of Population Health, Division of General Medicine and Clinical Innovation
Education
MD, University of Tennessee College of Medicine
MSc, Weill Cornell Graduate School of Medical Sciences
AB, Art and Archeology, Princeton University
Research Interests
Addiction pharmacotherapies, Primary care, Criminal justice
BIO
Joshua D. Lee is an Associate Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at NYU Langone Health. He is a clinician researcher focused on addiction pharmacotherapies, and is Director of the NYU ABAM Fellowship in Addiction Medicine. His research models the use of addiction pharmacotherapies in primary care and criminal justice populations. He has conducted multiple NIH and other clinical trials examining the use of extended-release naltrexone and buprenorphine opioid treatments in outpatient criminal justice involved-adults, in soon-to-be released jail inmates, and in community detox settings. Research on extended-release naltrexone for alcohol treatment has focused on primary care medical management. Dr. Lee graduated Princeton University (AB), the University of Tennessee School of Medicine (MD), and Weill Cornell Graduate School of Medical Sciences (MSc). He completed a residency and chief residency in Primary Care Internal Medicine at NYU/Bellevue Hospital Center and is certified in Addiction Medicine. He is currently an attending physician at Bellevue Hospital and in the New York City jails.
Projects
Principal Investigator, Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017. Active
Principal Investigator, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-Involved Adults. Active
Principal Investigator, Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-Entry. Completed
Principal Investigator, Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care. Completed
Publications

Recent

Tsui JI, Campbell ANC, Pavlicova M, Choo TH, Lee JD, Cook RR, Shulman M, Nunes EV, Rotrosen J (2022).
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone
Drug and Alcohol Dependence, 236, 109469. doi: 10.1016/j.drugalcdep.2022.109469.

Tofighi B, Durr M, Marini C, Lewis CF, Lee JD (2022).
A mixed-methods evaluation of the feasibility of a medical management-based text messaging intervention combined with buprenorphine in primary care
Substance Abuse: Research and Treatment, 16, 11782218221078253. doi: 10.1177/11782218221078253. PMCID: PMC8958716.

Cheng A, Badolato R, Segoshi A, McDonald R, Malone M, Vasudevan K, Badiei B, Sugarman A, Macdonald R, Mangat J, Giftos J, Lee JD, Tofighi B (2022).
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: An in-depth qualitative study
Addiction Science and Clinical Practice, 17 (1), 4. doi: 10.1186/s13722-022-00288-4. PMCID: PMC8800291.

Berk J, Del Pozo B, Rich JD, Lee JD (2021).
Injecting opioid use disorder treatment in jails and prisons: The potential of extended-release buprenorphine in the carceral setting
Journal of Addiction Medicine [Epub 2021 Dec 23]. doi: 10.1097/ADM.0000000000000942.

Greiner MG, Shulman M, Choo TH, Scodes J, Pavlicova M, Campbell ANC, Novo P, Fishman M, Lee JD, Rotrosen J, Nunes EV (2021).
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse
Journal of Substance Abuse Treatment, 131, 108447. doi: 10.1016/j.jsat.2021.108447. PMCID: PMC8556394.


Notable

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP (2016).
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
New England Journal of Medicine, 374 (13), 1232-1242. doi: 10.1056/NEJMoa1505409. PMCID: PMC5454800.

Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN (2015).
Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial
Addiction, 110 (6), 1008-1014. doi: 10.1111/add.12894.

Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch M (2012).
Buprenorphine-naloxone maintenance following release from jail
Substance Abuse, 33 (1), 40-47. doi: 10.1080/08897077.2011.620475. PMCID: PMC3310898.

Dr. Lee's MyBibliography Profile
Selected Press